FTAI FRAUD LAWSUIT: FTAI Aviation Ltd. Investors that Lost Money may have been affected by Fraud — Contact BFA Law by March 18 Class Action Deadline (NASDAQ:FTAI)

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against FTAI Aviation Ltd. (NASDAQ: FTAI) and certain of its senior executives for potential violations of the federal securities laws.

If you invested in FTAI Aviation, you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/ftai-aviation-ltd
.

Investors have until March 18, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in FTAI Aviation securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Shannahan v. FTAI Aviation Ltd., et al., No. 25-cv-00541.

Why was FTAI Aviation Sued for Securities Fraud?

FTAI Aviation is an integrated full-service provider of aftermarket power and maintenance for commercial jet engines. In its Q3 2024 financial report, FTAI Aviation reported quarterly revenue in its Aerospace Products segment of approximately $303 million, representing an approximately 155% increase over the prior year’s quarter.

The complaint alleges that in reality, the majority of FTAI Aviation’s adjusted EBITDA in the Aerospace Products segment comes from gains on sales, which are less recurring in nature, and that FTAI Aviation engaged in channel stuffing to inflate its 2023 financial results.

The Stock Declines as the Truth is Revealed

On January 15, 2024, prominent investment research firm Muddy Waters published a report titled “FTAI Aviation: Financial Engineering and Accounting Manipulation in the MRO Business.” Based on an investigation that included consulting an industry expert with 20+ years of experience (that was also a former FTAI Aviation executive) and other industry insiders, Muddy Waters claims that FTAI Aviation has been recording one-time engine sales as Maintenance Repair & Overhaul (MRO) revenue in its Aerospace Products segment. Muddy Waters states that this has enabled the company to present a misleading narrative of growth in its Aerospace Products revenue, which has benefited insider sellers. The research firm estimates that the majority of FTAI Aviation’s adjusted EBITDA in the Aerospace Products segment comes from gains on sales, which are less recurring in nature, and that FTAI Aviation engaged in channel stuffing to inflate its 2023 financial results.

The news caused a significant decline in the price of FTAI Aviation stock. On January 15, 2025, the price of the company’s stock fell 24%, from a closing price of $153.29 per share on January 14, 2025, to $116.08 per share on January 15, 2025.

On January 21, 2025, FTAI Aviation announced that its Audit Committee had commenced a review into the Muddy Waters allegations and that its Annual Report may be delayed. This news caused a significant decline in the price of FTAI Aviation stock. On January 21, 2025, the price of the company’s stock fell 23%, from a closing price of $112.38 per share on January 17, 2025, to an opening price of $86.37 per share on January 21, 2025.

Click here for more information:

https://www.bfalaw.com/cases-investigations/ftai-aviation-ltd

.

What Can You Do?

If you invested in FTAI Aviation, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/ftai-aviation-ltd

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/ftai-aviation-ltd

Attorney advertising. Past results do not guarantee future outcomes.



TTD FRAUD REMINDER: Trade Desk, Inc. Investors that Lost Money may have been affected by Fraud — Contact BFA Law (NASDAQ:TTD)

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The Trade Desk, Inc. (NASDAQ: TTD) for potential violations of the federal securities laws.

If you invested in Trade Desk, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/the-trade-desk-inc.

Why is Trade Desk being Investigated?

Trade Desk is an advertising technology company that offers ad buyers the ability to create and manage data-driven digital advertising campaigns across ad formats and channels. During the relevant period, Trade Desk stated that it was seeing “massive benefits” surrounding the launch of its next-generation platform, Kokai, and that although it was “already seeing the results of Kokai performance today,” it was “just getting started.”

In truth, when these statements were made, the rollout of Trade Desk’s Kokai platform apparently faltered, contributing to Trade Desk’s first revenue miss in 33 quarters.

The Stock Declines as the Truth is Revealed

On February 12, 2025, after market hours, Trade Desk reported its fourth quarter 2024 financial results. The company reported disappointing revenue of $741 million, well below its guidance of “at least” $756 million in revenue. During the same-day earnings call, the company admitted that “Kokai rolled out slower than we anticipated” as the company was still “trying to understand what the customer needs.” On this news, the price of Trade Desk stock fell over 30% during the course of trading on February 13, 2025, from a closing price of $122.23 per share on February 12, 2025.

Click here for more information:

https://www.bfalaw.com/cases-investigations/the-trade-desk-inc

.

What Can You Do?

If you invested in Trade Desk you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/the-trade-desk-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/the-trade-desk-inc

Attorney advertising. Past results do not guarantee future outcomes.



NXT FRAUD LAWSUIT: Nextracker Inc. Investors that Lost Money may have been affected by Fraud — Contact BFA Law by February 25 Class Action Deadline (NASDAQ:NXT)

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Nextracker Inc. (NASDAQ: NXT) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Nextracker, you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/nextracker-inc
.

Investors have until February 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Nextracker stock. The case is pending in the U.S. District Court for the Northern District of California and is captioned Weber v. Nextracker Inc., et al., No. 24-cv-9467.

Why was Nextracker Sued for Securities Fraud?

Nextracker provides software that enables solar panels to follow the sun’s movement across the sky and related products and services. Nextracker’s customers include solar project developers and owners.

During the relevant period, Nextracker minimized the impact of project delays on its business, claiming that the delays were isolated to individual projects, that the Company was better at managing project timelines than its competitors, and that favorable demand trends more than offset any adverse effects stemming from project delays.

In truth, Nextracker’s ability to convert its backlog to revenue was hampered by permitting delays as well as panel availability and interconnection to a far greater extent than previously disclosed. In addition, the purported favorable demand trends and Nextracker’s management of project timeliness had not effectively offset the negative impact of these project delays.

The Stock Declines as the Truth is Revealed

On August 1, 2024, Nextracker announced its financial results for its fiscal Q1 2025, revealing that revenue declined to $720 million, from $737 million in the prior quarter, and failed to raise guidance for the first time since it became a public company. On the same-day earnings call, Nextracker admitted that “it is taking longer for projects to be fulfilled in real life due to” “construction permits or interconnection delays.” The Company also stated that only “80% of that backlog is expected to be realized over the next eight quarters,” which it acknowledged was “a bit of a shift” from its prior commentary on its backlog conversion rate.

On this news, the price of Nextracker stock fell 15% over the course of two trading days, from a closing price of $46.83 per share on August 1, 2024 to $39.81 per share on August 5, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/nextracker-inc

.

What Can You Do?

If you invested in Nextracker you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/nextracker-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/nextracker-inc

Attorney advertising. Past results do not guarantee future outcomes.



Allstate Announces January 2025 Catastrophe Losses and Policies in Force

Allstate Announces January 2025 Catastrophe Losses and Policies in Force

NORTHBROOK, Ill.–(BUSINESS WIRE)–
The Allstate Corporation (NYSE: ALL) today announced estimated catastrophe losses for the month of January of $1.08 billion or $849 million, after-tax.

Catastrophe losses included three events with approximately $1.07 billion related to the California wildfires. The California wildfire event estimate includes reinsurance reinstatement premiums, an estimated California FAIR Plan assessment and is net of estimated reinsurance recoveries of $1.40 billion.

Allstate Protection policies in force are as follows:

Allstate Protection Policies in Force (1)

(in thousands)

 

January 31,

2025

 

December

31, 2024

 

January 31,

2024

 

Jan. 31, 2025 v

Dec. 31, 2024

 

Jan. 31, 2025 v

Jan. 31, 2024

Auto

 

24,835

 

24,936

 

25,155

 

(0.4) %

 

(1.3) %

Homeowners

 

7,521

 

7,511

 

7,341

 

0.1 %

 

2.5 %

Other personal lines

 

4,866

 

4,870

 

4,850

 

(0.1) %

 

0.3 %

Commercial lines

 

204

 

213

 

280

 

(4.2) %

 

(27.1) %

Total

 

37,426

 

37,530

 

37,626

 

(0.3) %

 

(0.5) %

(1) Policy counts are based on items rather than customers. A multi-car customer would generate multiple item (policy) counts, even if all cars were insured under one policy. Lender-placed policies are excluded from policy counts because relationships are with the lenders.

Financial information, including material announcements about The Allstate Corporation, is routinely posted on www.allstateinvestors.com.

Forward-Looking Statements

This news release contains “forward-looking statements” that anticipate results based on our estimates, assumptions and plans that are subject to uncertainty. These statements are made subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements do not relate strictly to historical or current facts and may be identified by their use of words like “plans,” “seeks,” “expects,” “will,” “should,” “anticipates,” “estimates,” “intends,” “believes,” “likely,” “targets” and other words with similar meanings. We believe these statements are based on reasonable estimates, assumptions and plans. However, if the estimates, assumptions or plans underlying the forward-looking statements prove inaccurate or if other risks or uncertainties arise, actual results could differ materially from those communicated in these forward-looking statements. Factors that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements may be found in our filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” section in our most recent annual report on Form 10-K. Forward-looking statements are as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statement.

Nick Nottoli

Media Relations

(847) 402-5600

Allister Gobin

Investor Relations

(847) 402-2800

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Finance Natural Disasters Environment Professional Services Insurance

MEDIA:

Logo
Logo

Allstate and NACDA unveil nominees for inaugural Good Works Team, celebrating all college sports, athletes

Allstate and NACDA unveil nominees for inaugural Good Works Team, celebrating all college sports, athletes

Nearly 200 student-athletes across collegiate winter sports are recognized for giving back to their communities as part of the newly expanded Good Works Team.

NORTHBROOK, Ill.–(BUSINESS WIRE)–
Allstate and the National Association of Collegiate Directors of Athletics (NACDA) proudly honor 193 student-athletes excelling in academics, sports and community impact. Nominated by athletics administrators, conference office staff, and coaches, these student-athletes embody leadership, service and character and will now be considered for selection to the inaugural Allstate NACDA Good Works Team (Winter).

“These young women and men are more than competitors – they’re leaders, changemakers and role models,” said Holly Rowe, ESPN reporter, play-by-play commentator and Allstate NACDA Ambassador. “Their influence extends beyond the game, shaping communities and teaching others the value of leadership skills, like empathy, resilience and integrity, which will last a lifetime.”

Nominees at-a-glance

The 2024-25 Allstate NACDA Good Works Team (Winter) celebrates 193 nominees – 115 women and 78 men – spanning 17 sports, including basketball, swimming and diving, gymnastics, ice hockey and many others. Nominees include:

  • Sierra Ballard – Louisiana State University, Women’s Gymnastics
  • Paige Bueckers – University of Connecticut, Women’s Basketball
  • Torie Buerger – University of Kentucky, Women’s Swimming & Diving
  • Taylor Heie – Umpqua Community College, Women’s Indoor Track & Field
  • KaLynn Irey – Stephens College, Women’s Basketball
  • Sion James – Duke University, Men’s Basketball
  • Emmanuela Katou-Kouami – University of the District of Columbia, Women’s Indoor Track & Field
  • Colby Kern – Saint John’s University (Minn.), Men’s Swimming & Diving
  • Sophia Kyrkostas – SUNY Oswego, Women’s Hockey
  • Ishmael Leggett – University of Pittsburgh, Men’s Basketball
  • Jahmai Mashak – University of Tennessee, Men’s Basketball
  • Jojo Randby – University of Nebraska-Lincoln, Women’s Swimming & Diving
  • Kiani Saxon – Missouri Western State University, Men’s Basketball
  • Jacob Truscott – University of Michigan, Men’s Ice Hockey

The full list of 2024-25 Allstate NACDA Winter Good Works Team nominees is available here.

Nominations can be submitted for up to one female and one male student-athlete from each winter sport at an institution. Eligible schools and athletics programs must represent one of five intercollegiate athletics divisions: NCAA Division I, II, III, NAIA and Junior/Community Colleges. Nominees must have completed at least one year (two semesters) of college coursework at a two-year or four-year institution.

The final 20-member team

A distinguished Selection Committee will select 20 nominees – 10 female and 10 male student-athletes – to join the 2024-25 Allstate NACDA Good Works Team (Winter). The committee includes Rowe, ESPN analyst and former University of Texas and NFL linebacker Sam Acho, and other esteemed members:

  • Elizabeth Brady– Chief marketing, customer and communications officer, Allstate
  • Ross Bjork – Senior vice president and Wolfe Foundation-Eugene Smith Endowed athletics director, The Ohio State University; NACDA president
  • Dan Guerrero – Retired director of athletics, UCLA; NACDA past president
  • Brian Henderson – Athletics director/assistant vice president of student engagement and inclusion, Patrick & Henry Community College; NACDA Executive Committee, NATYCAA 1st vice president
  • Reagan Rossi – Vice president of athletics, College of Idaho; NACDA Executive Committee, NAIA-ADA president
  • Etienne Thomas – Director of athletics, Winston-Salem State University; NACDA Executive Committee, D2 ADA Board of Directors
  • Natalie Winkelfoos – Associate vice president for athletics advancement and Delta Lodge director of athletics & physical education, Oberlin College; NACDA Executive Committee

A legacy of college sports

Announced in December, the Allstate NACDA Good Works Team builds on the legacy of the Allstate AFCA Good Works Team®, which has celebrated college football players’ good work off the field since 1992. Now, 60 more student-athletes across all sports and all divisions will be honored annually – three groups of 20 representing the fall, winter and spring collegiate athletics seasons.

“Athletes in sports that don’t always make the headlines demonstrate the same dedication to service and leadership as any other competitor,” said Elizabeth Brady, Allstate’s chief marketing, customer and communications officer. “The overwhelmingly positive response to our first-ever Allstate NACDA Good Works Team shows how much this spotlight and support matters. We’re honored to share the stories of these inspiring student-athletes.”

About Allstate

The Allstate Corporation (NYSE: ALL) protects people from life’s uncertainties with a wide array of protection for autos, homes, electronic devices and identity theft. Products are available through a broad distribution network, including Allstate agents, independent agents and major retailers, online and at the workplace. Allstate is widely known for the slogan “You’re in Good Hands with Allstate.” For more information, visit allstate.com.

About NACDA

Now in its 60th year, NACDA is the professional and educational Association for more than 24,000 college athletics administrators at more than 2,300 institutions throughout the United States, Canada and Mexico. NACDA manages 19 professional associations and four foundations. In addition to virtual programming, NACDA hosts and/or has a presence at seven major professional development events in-person annually. The NACDA & Affiliates Convention is the largest gathering of collegiate athletics administrators in the country. For more information, visit www.nacda.com.

Allstate Media Team

(847) 402-5600

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Professional Services Education Sports Other Sports Insurance University

MEDIA:

Logo
Logo

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

  • Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that Mai-Britt Zocca, PhD, President and CEO, will present a company overview at the 45th Annual Cowen Health Care Conference to be held March 3-5, 2025 in Boston, MA. Dr. Zocca, joined by Amy Sullivan, CFO, and Qasim Ahmad, MD, CMO, will also be hosting one-on-one investor meetings during the conference.

Presentation Details

Date and Time: Wednesday, March 5, 2025, 2:30-3:00 PM EST
Presenter: Mai-Britt Zocca, PhD, President & CEO
Webcast Link: https://wsw.com/webcast/cowen177/iobt/2022522

A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com for 90 days.

About Cylembio™

Cylembio™ (imsapepimut and etimupepimut, adjuvanted), is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO1) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating Cylembio in combination with pembrolizumab as first line treatment in patients with advanced solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating Cylembio in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. Enrollment in the three ongoing company-sponsored clinical trials is now complete.

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead investigational cancer vaccine candidate, Cylembio™ (imsapepimut and etimupepimut, adjuvanted) also known as IO102-IO103 in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.

For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).

Cylembio is a trademark of IO Biotech ApS.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

Contact:

Investors

Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
[email protected]

Media

Julie Funesti
Edelman
917-498-1967
[email protected]



CRC Innovations and Ameresco Announce Over $200 Million Contract to Promote Energy Savings and Capital Improvements at Three Army Locations

CRC Innovations and Ameresco Announce Over $200 Million Contract to Promote Energy Savings and Capital Improvements at Three Army Locations

5,000 military homes to benefit from infrastructure resiliency efforts

WARWICK, R.I. & FRAMINGHAM, Mass.–(BUSINESS WIRE)–CRC Innovations, an integrated energy and infrastructure solutions pioneer, and Ameresco, Inc., (NYSE: AMRC), a leading energy solutions provider dedicated to helping customers navigate the energy transition, today announced an over $200 million Energy Saving Performance Contract (ESPC) to provide capital improvements at U.S. Army military housing at Fort Bragg, N.C.; Fort Meade, Md.; and Fort Sill, Okla.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220235738/en/

Strengthening military homes through resilient infrastructure. (Photo: Business Wire)

Strengthening military homes through resilient infrastructure. (Photo: Business Wire)

This multi-site project is expected to provide quality-of-life improvements for service members and their families, while also reducing annual electrical consumption by 40% and natural gas consumption by 50%. The initiatives will modernize living conditions and enhance energy efficiency across 5,000 homes, affecting more than 15,000 residents. The communities are owned and operated by Corvias, a long-standing solutions partner to the Department of Defense.

“CRC is honored to enable efficiency technologies that support service members and their families and provide a clear path to meeting the readiness and resiliency goals of the Army,” said Pablo Varela, CRC Innovations Executive Vice President. “We take pride in knowing that our efforts directly impact the well-being of service members and their families and contribute to military readiness.”

The high impact energy measures include replacing existing HVAC units with sustainable, renewable energy-sourced systems using ground source heat pumps manufactured in Oklahoma, as well as installing new electricity panels and new meters.

“This project will not only improve on-post living conditions, but also serve as a model for energy efficiency and resiliency in government facilities across the U.S.,” said Nicole Bulgarino, President of Federal Solutions and Utility Infrastructure at Ameresco. “By upgrading all heating and cooling equipment to high-efficiency geothermal systems, we are enhancing comfort and achieving significant energy savings for U.S. Army personnel consistent with infrastructure strength and security goals.”

The joint effort is expected to provide more than $12.4 million in annual utility and operational cost savings. Improvements for the sites are financed by the future savings generated by the implementation. Other ESPC benefits include improved heating and cooling, resiliency during extreme weather conditions, and reduced safety hazards.

For additional information CRC, visit https://www.crcinnovations.com/

For additional information on Ameresco and its energy performance contracting, visit www.ameresco.com/espc-energy-savings-performance-contract/

About CRC Innovations

CRC Innovations is focused on transforming mission critical energy infrastructure. We collaborate to strengthen community resilience through innovative solutions spanning energy efficiency, renewable generation, distribution, and storage. Our distinctive approach modernizes core infrastructure by unlocking alternative funding and reducing risk for military housing communities, the Department of Defense, and utility partners. By leveraging cutting-edge technology, we create future proof energy ecosystems that enhance mission capabilities and ensure security. Our commitment is to be a trusted resilience partner, delivering customized solutions that create enduring value and improve quality of life. For more information, visit www.crcinnovations.com.

About Ameresco, Inc.

Founded in 2000, Ameresco, Inc. (NYSE:AMRC) is a leading energy solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the global energy transition. Our comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. As a trusted full-service partner, Ameresco shows the way by reducing energy use and delivering diversified generation solutions to Federal, state and local governments, utilities, educational and healthcare institutions, housing authorities, and commercial and industrial customers. Headquartered in Framingham, MA, Ameresco has more than 1,500 employees providing local expertise in North America and Europe. For more information, visit www.ameresco.com.

The announcement of a customer’s entry into a project contract is not necessarily indicative of the timing or amount of revenue from such contract, of Ameresco’s overall revenue for any particular period or of trends in Ameresco’s overall total project backlog. This project was included in Ameresco’s previously reported contracted backlog as of September 30, 2024.

Media

CRC Innovations: [email protected]

Ameresco: Leila Dillon, 508-661-2264, [email protected]

KEYWORDS: United States North America Rhode Island Massachusetts Maryland Oklahoma North Carolina

INDUSTRY KEYWORDS: Oil/Gas Building Systems Residential Building & Real Estate Contracts Commercial Building & Real Estate Alternative Energy Construction & Property Energy Sustainability Manufacturing Defense Environment Military Urban Planning Utilities HVAC

MEDIA:

Photo
Photo
Strengthening military homes through resilient infrastructure. (Photo: Business Wire)
Logo
Logo
Logo
Logo

Charles River Associates (CRA) Reports Fourth-Quarter and Full-Year 2024 Financial Results

Charles River Associates (CRA) Reports Fourth-Quarter and Full-Year 2024 Financial Results

Broad-based Contributions Drive Record Revenue and Profitability in Fiscal 2024

Fourth Quarter Revenue Increases 9.2%Year Over Year

Board Expands Share Repurchase Authorization by $45 Million

BOSTON–(BUSINESS WIRE)–Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced financial results for the fourth quarter and fiscal year ended December 28, 2024.

“CRA achieved another record year, surpassing fiscal 2023’s revenue milestone,” said Paul Maleh, CRA’s President and Chief Executive Officer. “Strong top-line growth drove even greater increases in net income, earnings per diluted share, and EBITDA. For the fourth quarter, we continued to see strength across our portfolio of services. Revenue increased 9.2% compared with the fourth quarter of fiscal 2023 to $176.4 million. Three practices—Energy, Finance, and Intellectual Property—led the way, each generating double-digit revenue growth, while our Antitrust & Competition Economics, Labor & Employment, Risk, Investigations & Analytics and Life Sciences practices achieved year-over-year growth. Our North American and international operations both contributed to the quarter’s revenue growth, increasing 7.8% and 15.7%, respectively.”

Highlights for Fourth Quarter Fiscal 2024

  • Revenue grew 9.2% year over year to $176.4 million.
  • Utilization was 78% and quarter-end headcount decreased 5.8% year over year.
  • Net income increased 30.8% year over year to $15.0 million, or 8.5% of revenue, compared with $11.5 million, or 7.1% of revenue, in the fourth quarter of fiscal 2023; non-GAAP net income increased 21.2% year over year to $14.0 million, or 7.9% of revenue, compared with $11.5 million, or 7.1% of revenue, in the fourth quarter of fiscal 2023.
  • Earnings per diluted share increased 34.6% year over year to $2.18 from $1.62 in the fourth quarter of fiscal 2023; non-GAAP earnings per diluted share increased 24.5% year over year to $2.03 from $1.63 in the fourth quarter of fiscal 2023.
  • Non-GAAP EBITDA increased 28.4% to $24.4 million, or 13.9% of revenue, compared with $19.0 million, or 11.8% of revenue, in the fourth quarter of fiscal 2023.
  • On a constant currency basis relative to the fourth quarter of fiscal 2023, revenue, GAAP net income, and earnings per diluted share would have been lower by $0.6 million, $0.1 million, and $0.01 per diluted share, respectively. Non-GAAP net income and non-GAAP earnings per diluted share would have been lower by $0.1 million and $0.01 per diluted share, respectively. Non-GAAP EBITDA would have remained unchanged.
  • CRA returned $3.4 million of capital to its shareholders via dividend payments.

Highlights for Full-Year Fiscal 2024

  • Revenue grew 10.2% year over year to $687.4 million with company-wide utilization of 75%.
  • GAAP net income increased 21.2% year over year to $46.7 million, or 6.8% of revenue, or $6.74 per diluted share, compared with $38.5 million, or 6.2% of revenue, or $5.39 per diluted share for the full year fiscal 2023. Non-GAAP net income increased 35.0% year over year to $52.6 million, or 7.7% of revenue, or $7.60 per diluted share, compared with $39.0 million, or 6.2% of revenue, or $5.46 per diluted share for the full year fiscal 2023.
  • Non-GAAP EBITDA grew 32.4% to $90.4 million, or 13.2% of revenue, compared with $68.3 million, or 10.9% of revenue, in fiscal 2023.
  • On a constant currency basis relative to fiscal 2023, revenue, GAAP net income, and earnings per diluted share would have been lower by $2.2 million, $0.4 million, and $0.05 per diluted share, respectively. Non-GAAP net income, non-GAAP earnings per diluted share, and non-GAAP EBITDA would have been lower by $0.3 million, $0.05 per diluted share, and $0.4 million, respectively.
  • For fiscal 2024, CRA returned $45.6 million of capital to its shareholders, consisting of $12.3 million in dividend payments and $33.3 million in share repurchases of approximately 206,000 shares.

Management Commentary and Financial Guidance

“CRA reported revenue for fiscal 2024 of $687.4 million, or $685.2 million on a constant currency basis relative to fiscal 2023,” said Maleh. “Full-year, non-GAAP EBITDA was $90.4 million, or $90.0 million on a constant currency basis relative to fiscal 2023. Non-GAAP EBITDA margin was 13.1% on a constant currency basis. This performance exceeds the top end of our previously stated financial guidance for fiscal 2024.”

“Our fiscal 2024 financial performance demonstrates our continued strength in the marketplace. For full-year fiscal 2025, on a constant currency basis relative to fiscal 2024, we expect revenue in the range of $715 million to $735 million, and non-GAAP EBITDA margin in the range of 12.0% to 13.0%. While we are pleased with CRA’s strong performance in 2024, we remain mindful that uncertain global macroeconomic, business, and political conditions can affect our business.”

CRA does not provide reconciliations of its annual non-GAAP EBITDA margin guidance to GAAP net income margin because the Company is unable to estimate with reasonable certainty unusual gains or charges, foreign currency exchange rates, and the resulting effect of these items, and of equity awards, on CRA’s taxes without unreasonable effort. These items are uncertain, depend on various factors, and may have a material effect on CRA’s results computed in accordance with GAAP. A reconciliation between the historical GAAP and non-GAAP financial measures presented in this release is provided in the financial tables at the end of this release.

Share Repurchase Expansion and Quarterly Dividend

On February 20, 2025, CRA’s Board of Directors authorized a $45.0 million expansion of the Company’s existing share repurchase program, in addition to the $13.1 million currently remaining under the program. CRA may repurchase shares of its common stock in the open market or in privately negotiated transactions in accordance with applicable insider trading and other securities laws and regulations. The timing, amount and extent to which CRA repurchases shares will depend upon market conditions and other factors it may consider in its sole discretion.

The Board of Directors also authorized a quarterly cash dividend of $0.49 per common share, payable on March 14, 2025 to shareholders of record as of March 4, 2025. CRA expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain subject to the discretion of CRA’s Board of Directors.

Conference Call Information and Prepared CFO Remarks

CRA will host a conference call today at 10:00 a.m. ET to discuss its fourth-quarter and fiscal-year 2024 financial results. To listen to the live call, please visit the “Investor Relations” section of CRA’s website at http://www.crai.com, or dial (877) 709-8155 or (201) 689-8881. An archived version of the webcast will be available on CRA’s website for one year.

In combination with this press release, CRA has posted prepared remarks by its CFO Dan Mahoney under “Quarterly Earnings” in the “Investor Relations” section on CRA’s website at http://www.crai.com. These remarks are offered to provide the investment community with additional background on CRA’s financial results prior to the start of the conference call.

About Charles River Associates (CRA)

Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Instagram, and Facebook.

NON-GAAP FINANCIAL MEASURES

In this release, CRA has supplemented the presentation of its financial results calculated in accordance with U.S. generally accepted accounting principles or “GAAP” with the following financial measures that are not calculated in accordance with GAAP: non‑GAAP net income, non‑GAAP earnings per diluted share and non‑GAAP EBITDA. CRA believes that the non-GAAP financial measures described in this press release are important to management and investors because these measures supplement the understanding of CRA’s ongoing operating results and financial condition. In addition, these non-GAAP measures are used by CRA in its budgeting process, and the non-GAAP adjustments are made to the performance measures for some of CRA’s performance-based compensation.

As used herein, CRA defines non-GAAP EBITDA as net income before interest expense (net), provision for income taxes, and depreciation and amortization further adjusted for the impact of certain items that we do not consider indicative of our core operating performance, such as non-cash amounts relating to valuation changes in contingent consideration, acquisition-related costs, foreign currency (gains) losses, net, restructuring costs and related tax effects. Non-GAAP net income and non-GAAP earnings per diluted share also exclude non-cash amounts relating to valuation changes in contingent consideration, acquisition-related costs, foreign currency (gains) losses, net, restructuring costs and related tax effects. This release also presents certain current fiscal period financial measures on a “constant currency” basis in order to isolate the effect that foreign currency exchange rate fluctuations can have on CRA’s financial results. These constant currency measures are determined by recalculating the current fiscal period local currency financial measure using the specified corresponding prior fiscal period’s foreign exchange rates.

All of the non-GAAP financial measures referred to above should be considered in conjunction with, and not as a substitute for, the GAAP financial information presented in this release. EBITDA and the financial measures identified in this release as “non-GAAP” are reconciled to their GAAP comparable measures in the financial tables appended to the end of this press release. In evaluating these non-GAAP financial measures, note that the non-GAAP financial measures used by CRA may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

SAFE HARBOR STATEMENT

Statements in this press release concerning our future business, operating results and financial condition, including those concerning guidance on future revenue and non-GAAP EBITDA margin, the impact of exchange rate fluctuations on our financial results, our expectations regarding continued growth, our expectations regarding the payment of any future quarterly dividends and the level and extent of any purchases under our expanded share repurchase program, and statements using the terms “outlook,” “expect,” or similar expressions, are “forward-looking” statements as defined in Section 21 of the Exchange Act. These statements are based upon our current expectations and various underlying assumptions. Although we believe there is a reasonable basis for these statements and assumptions, and these statements are expressed in good faith, these statements are subject to a number of additional factors and uncertainties. Our actual revenue and non-GAAP EBITDA margin in fiscal 2025 on a constant currency basis relative to fiscal 2024 could differ materially from the guidance presented herein, and our actual performance and results may differ materially from the performance and results contained in or implied by the forward-looking statements made herein, due to many important factors. These factors include, but are not limited to, the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions; the timing of engagements for our services; the effects of competitive services and pricing; our ability to attract and retain key employee or non-employee experts; the inability to integrate and utilize existing consultants and personnel; the decline or reduction in project work or activity; global economic conditions including less stable political and economic environments; foreign currency exchange rate fluctuations; unanticipated expenses and liabilities; risks inherent in international operations; changes in tax law or accounting standards, rules, and regulations; our ability to collect on forgivable loans should any become due; and professional and other legal liability or settlements. Additional risks and uncertainties are discussed in our periodic filings with the Securities and Exchange Commission under the heading “Risk Factors.” The inclusion of such forward-looking information should not be regarded as our representation that the future events, plans, or expectations contemplated will be achieved. Except as may be required by law, we undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.

 
CRA INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE FISCAL QUARTERS AND FISCAL YEAR-TO-DATE PERIODS ENDED
DECEMBER 28, 2024 COMPARED TO DECEMBER 30, 2023
(IN THOUSANDS, EXCEPT PER SHARE DATA)
 
Fiscal Quarter Ended Fiscal Year-to-Date Period Ended
December 28,
2024
As a % of
Revenue
December 30,
2023
As a % of
Revenue
December 28,
2024
As a % of
Revenue
December 30,
2023
As a % of
Revenue
Revenues

$

176,435

 

100.0

%

$

161,613

 

100.0

%

$

687,414

 

100.0

%

$

623,976

 

100.0

%

Cost of services (exclusive of depreciation and amortization)

 

120,541

 

68.3

%

 

112,688

 

69.7

%

 

479,936

 

69.8

%

 

439,751

 

70.5

%

Selling, general and administrative expenses

 

31,266

 

17.7

%

 

28,979

 

17.9

%

 

125,050

 

18.2

%

 

115,116

 

18.4

%

Depreciation and amortization

 

3,174

 

1.8

%

 

2,801

 

1.7

%

 

11,677

 

1.7

%

 

11,564

 

1.9

%

Income from operations

 

21,454

 

12.2

%

 

17,145

 

10.6

%

 

70,751

 

10.3

%

 

57,545

 

9.2

%

 
Interest expense, net

 

(1,013

)

-0.6

%

 

(600

)

-0.4

%

 

(4,417

)

-0.6

%

 

(3,812

)

-0.6

%

Foreign currency gains (losses), net

 

1,145

 

0.6

%

 

(987

)

-0.6

%

 

(92

)

%

 

(1,445

)

-0.2

%

Income before provision for income taxes

 

21,586

 

12.2

%

 

15,558

 

9.6

%

 

66,242

 

9.6

%

 

52,288

 

8.4

%

Provision for income taxes

 

6,599

 

3.7

%

 

4,099

 

2.5

%

 

19,589

 

2.8

%

 

13,807

 

2.2

%

Net income

$

14,987

 

8.5

%

$

11,459

 

7.1

%

$

46,653

 

6.8

%

$

38,481

 

6.2

%

 
Net income per share:
Basic

$

2.21

 

$

1.65

 

$

6.82

 

$

5.48

 

Diluted

$

2.18

 

$

1.62

 

$

6.74

 

$

5.39

 

 
Weighted average number of shares outstanding:
Basic

 

6,763

 

 

6,954

 

 

6,821

 

 

7,008

 

Diluted

 

6,866

 

 

7,057

 

 

6,908

 

 

7,118

 

 
CRA INTERNATIONAL, INC.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
FOR THE FISCAL QUARTERS AND FISCAL YEAR-TO-DATE PERIODS ENDED
DECEMBER 28, 2024 COMPARED TO DECEMBER 30, 2023
(IN THOUSANDS, EXCEPT PER SHARE DATA)
 
Fiscal Quarter Ended Fiscal Year-to-Date Period Ended
December 28,
2024
As a % of
Revenue
December 30,
2023
As a % of
Revenue
December 28,
2024
As a % of
Revenue
December 30,
2023
As a % of
Revenue
Revenues

$

176,435

 

100.0

%

$

161,613

 

100.0

%

$

687,414

 

100.0

%

$

623,976

 

100.0

%

 
Net income

$

14,987

 

8.5

%

$

11,459

 

7.1

%

$

46,653

 

6.8

%

$

38,481

 

6.2

%

Adjustments needed to reconcile GAAP net income to non-GAAP net income:
Non-cash valuation change in contingent consideration

 

(190

)

-0.1

%

 

(918

)

-0.6

%

 

(190

)

%

 

(866

)

-0.1

%

Restructuring (1)

 

 

%

 

 

%

 

8,176

 

1.2

%

 

 

%

Acquisition-related costs

 

 

%

 

 

%

 

 

%

 

22

 

%

Foreign currency (gains) losses, net

 

(1,145

)

-0.6

%

 

987

 

0.6

%

 

92

 

%

 

1,445

 

0.2

%

Tax effect on adjustments

 

340

 

0.2

%

 

13

 

%

 

(2,126

)

-0.3

%

 

(125

)

%

Non-GAAP net income

$

13,992

 

7.9

%

$

11,541

 

7.1

%

$

52,605

 

7.7

%

$

38,957

 

6.2

%

 
Non-GAAP net income per share:
Basic

$

2.06

 

$

1.66

 

$

7.69

 

$

5.54

 

Diluted

$

2.03

 

$

1.63

 

$

7.60

 

$

5.46

 

 
Weighted average number of shares outstanding:
Basic

 

6,763

 

 

6,954

 

 

6,821

 

 

7,008

 

Diluted

 

6,866

 

 

7,057

 

 

6,908

 

 

7,118

 

 
(1) Includes cash severance of $2.5M and non-cash charges of $5.7M associated with portfolio optimization actions.
 
CRA INTERNATIONAL, INC.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
FOR THE FISCAL QUARTERS AND FISCAL YEAR-TO-DATE PERIODS ENDED
DECEMBER 28, 2024 COMPARED TO DECEMBER 30, 2023
(IN THOUSANDS)
 
Fiscal Quarter Ended Fiscal Year-to-Date Period Ended
December 28,
2024
As a % of
Revenue
December 30,
2023
As a % of
Revenue
December 28,
2024
As a % of
Revenue
December 30,
2023
As a % of
Revenue
Revenues

$

176,435

 

100.0

%

$

161,613

 

100.0

%

$

687,414

 

100.0

%

$

623,976

 

100.0

%

 
Net income

$

14,987

 

8.5

%

$

11,459

 

7.1

%

$

46,653

 

6.8

%

$

38,481

 

6.2

%

Adjustments needed to reconcile GAAP net income to non-GAAP net income:
Non-cash valuation change in contingent consideration

 

(190

)

-0.1

%

 

(918

)

-0.6

%

 

(190

)

%

 

(866

)

-0.1

%

Restructuring (1)

 

 

%

 

 

%

 

8,176

 

1.2

%

 

 

%

Acquisition-related costs

 

 

%

 

 

%

 

 

%

 

22

 

%

Foreign currency (gains) losses, net

 

(1,145

)

-0.6

%

 

987

 

0.6

%

 

92

 

%

 

1,445

 

0.2

%

Tax effect on adjustments

 

340

 

0.2

%

 

13

 

%

 

(2,126

)

-0.3

%

 

(125

)

%

Non-GAAP net income

$

13,992

 

7.9

%

$

11,541

 

7.1

%

$

52,605

 

7.7

%

$

38,957

 

6.2

%

Adjustments needed to reconcile non-GAAP net income to non-GAAP EBITDA:
Interest expense, net

 

1,013

 

0.6

%

 

600

 

0.4

%

 

4,417

 

0.6

%

 

3,812

 

0.6

%

Provision for income taxes

 

6,259

 

3.5

%

 

4,086

 

2.5

%

 

21,715

 

3.2

%

 

13,932

 

2.2

%

Depreciation and amortization

 

3,174

 

1.8

%

 

2,801

 

1.7

%

 

11,677

 

1.7

%

 

11,564

 

1.9

%

Non-GAAP EBITDA

$

24,438

 

13.9

%

$

19,028

 

11.8

%

$

90,414

 

13.2

%

$

68,265

 

10.9

%

 
(1) Includes cash severance of $2.5M and non-cash charges of $5.7M associated with portfolio optimization actions.
CRA INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
 
December 28,
2024
December 30,
2023
 
Assets
Cash and cash equivalents

$

26,711

$

45,586

Accounts receivable and unbilled services, net

 

219,548

 

199,556

Other current assets

 

23,104

 

20,334

Total current assets

 

269,363

 

265,476

 
Property and equipment, net

 

45,205

 

38,176

Goodwill and intangible assets, net

 

100,953

 

101,185

Right-of-use assets

 

81,157

 

86,887

Other assets

 

74,761

 

61,487

Total assets

$

571,439

$

553,211

 
Liabilities and Shareholders’ Equity
Accounts payable

$

28,155

$

28,701

Accrued expenses

 

181,413

 

171,040

Current portion of lease liabilities

 

18,696

 

16,475

Other current liabilities

 

23,045

 

19,871

Total current liabilities

 

251,309

 

236,087

Non-current portion of lease liabilities

 

84,541

 

92,280

Other non-current liabilities

 

23,516

 

12,743

Total liabilities

 

359,366

 

341,110

 
Total shareholders’ equity

 

212,073

 

212,101

Total liabilities and shareholders’ equity

$

571,439

$

553,211

 
CRA INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
 
Year Ended
December 28,
2024
December 30,
2023
 
Operating activities:
Net income

$

46,653

 

$

38,481

 

Adjustments to reconcile net income to net cash provided by operating activities, net of effect of acquired businesses:
Non-cash items, net

 

29,316

 

 

26,197

 

Accounts receivable and unbilled services

 

(22,197

)

 

(2,860

)

Working capital items, net

 

(4,037

)

 

(1,746

)

Net cash provided by operating activities

 

49,735

 

 

60,072

 

 
Investing activities:
Purchases of property and equipment

 

(16,623

)

 

(2,366

)

Consideration paid for acquisitions, net

 

(1,500

)

 

(577

)

Net cash used in investing activities

 

(18,123

)

 

(2,943

)

 
Financing activities:
Issuance of common stock, principally stock options exercises

 

 

 

805

 

Borrowings under revolving line of credit

 

102,000

 

 

105,000

 

Repayments under revolving line of credit

 

(102,000

)

 

(105,000

)

Tax withholding payments reimbursed by shares

 

(3,209

)

 

(3,063

)

Cash dividends paid

 

(12,300

)

 

(10,807

)

Repurchase of common stock

 

(33,348

)

 

(31,417

)

Net cash used in financing activities

 

(48,857

)

 

(44,482

)

 
Effect of foreign exchange rates on cash and cash equivalents

 

(1,630

)

 

1,492

 

 
Net increase (decrease) in cash and cash equivalents

 

(18,875

)

 

14,139

 

Cash and cash equivalents at beginning of period

 

45,586

 

 

31,447

 

Cash and cash equivalents at end of period

$

26,711

 

$

45,586

 

 
Noncash investing and financing activities:
Increase (decrease) in accounts payable and accrued expenses for property and equipment

$

598

 

$

(91

)

Excise tax on share repurchases

$

(270

)

$

(247

)

Asset retirement obligations

$

191

 

$

 

Right-of-use assets obtained in exchange for lease obligations

$

10,084

 

$

3,198

 

Supplemental cash flow information:
Cash paid for taxes

$

21,444

 

$

14,011

 

Cash paid for interest

$

4,145

 

$

3,539

 

Cash paid for amounts included in operating lease liabilities

$

20,963

 

$

22,272

 

 

Dan Mahoney

Chief Financial Officer

Charles River Associates

617-425-3505

Nicholas Manganaro

Sharon Merrill Advisors

[email protected]

617-542-5300

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Consulting Professional Services Finance

MEDIA:

Stellantis Unveils STLA AutoDrive, Hands-Free and Eyes-Off Autonomous Technology for a New Era of Driving Comfort

Stellantis Unveils STLA AutoDrive, Hands-Free and Eyes-Off Autonomous Technology for a New Era of Driving Comfort

  • Stellantis-developed automated driving technology is ready for deployment.
  • Hands-Free and Eyes-Off (SAE Level 3) functionality available up to 60 km/h (37 mph), even at night and in challenging weather conditions.
  • STLA AutoDrive also enables Level 2 (hands on) and Level 2+ (hands off, eyes on) capabilities at higher speed, including Adaptive Cruise Control and lane centering functions.
  • Designed to evolve, with potential for higher speed operation up to 95 km/h (59 mph) and off-road capabilities.

AMSTERDAM, February 20, 2025 — Stellantis N.V. today unveiled STLA AutoDrive 1.0, the Company’s first in-house-developed automated driving system, delivering Hands-Free and Eyes-Off (SAE Level 3) functionality. STLA AutoDrive is a key pillar of Stellantis’ technology strategy, alongside STLA Brain and STLA Smart Cockpit, advancing vehicle intelligence, automation and user experience.

STLA AutoDrive enables automated driving at speeds up to 60 km/h (37 mph), reducing driver workload in stop-and-go traffic and giving back valuable time.

Ideal for commuters in dense urban areas, STLA AutoDrive will allow drivers to temporarily engage in non-driving tasks such as watching a movie, catching up on emails, reading a book or simply looking out the window, reclaiming valuable time.

“Helping drivers make the best use of their time is a priority,” said Ned Curic, Stellantis Chief Engineering and Technology Officer. “By handling routine driving tasks, STLA AutoDrive will enhance the driving experience, making time behind the wheel more efficient and enjoyable.”

The system is designed for simplicity: when traffic and environmental conditions align, drivers are notified that STLA AutoDrive is available. Once activated by a physical button, the system takes control, maintaining safe distances, adjusting speed, and managing steering and braking seamlessly based on traffic flow.

STLA AutoDrive continuously monitors its surroundings through an advanced suite of sensors to ensure high-precision awareness and reliable operation, even at night or in challenging weather conditions such as light rain or road spray. To maintain consistent performance, an automated sensor-cleaning system keeps critical components clear for optimal reliability and functionality.

Stellantis engineers have refined STLA AutoDrive to react quickly and naturally, ensuring that the system feels smooth, predictable and human-like in real-world conditions. Whether maintaining safe following distances or adjusting to merging traffic, the system operates seamlessly to provide a confident, stress-free drive.

At higher speeds, STLA AutoDrive offers the convenience of Adaptive Cruise Control and lane centering functions in Level 2 (hands-on) and Level 2+ (hands-off, eyes-on) modes.

Built on a scalable architecture, STLA AutoDrive is ready for deployment and can be adapted for global markets across Stellantis branded vehicles, ensuring a smooth rollout as commercial strategies align with market demand. The system is also cloud-connected, enabling continuous enhancements through over-the-air updates and real-time data integration for optimized performance.

STLA AutoDrive complies with applicable regulations in supported markets and requires drivers to remain seated, belted and ready to assume control when prompted. It also respects regional laws on driver conduct, including phone use restrictions.

STLA AutoDrive is designed as an evolving platform, with ongoing research and future advancements potentially capable of unlocking:

•    Hands-Free and Eyes-Off operation at higher speeds, up to 95 km/h (59 mph).

•    Enhanced off-road automation for select models.

With its focus on safety, flexibility and long-term adaptability, STLA AutoDrive represents Stellantis’ next step toward more intelligent, comfortable and intuitive driving experiences.

# # #


About Stellantis

Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is one of the world’s leading automakers aiming to provide clean, safe and affordable freedom of mobility to all. It’s best known for its unique portfolio of iconic and innovative brands including Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep

®

, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. Stellantis is executing its Dare Forward 2030, a bold strategic plan that paves the way to achieve the ambitious target of becoming a carbon net zero mobility tech company by 2038, with single-digit percentage compensation of the remaining emissions, while creating added value for all stakeholders. For more information, visit


www.stellantis.com

@Stellantis Stellantis Stellantis Stellantis

For more information, contact:

Fernão SILVEIRA +31 6 43 25 43 41 – [email protected]

Nathalie ROUSSEL +33 6 87 77 41 82 – [email protected]

[email protected]
www.stellantis.com

 

Attachment



Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation ‘Agnostic Diagnostics’ for Respiratory Viruses at the Point of Care

PR Newswire

International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness


BOSTON
, Feb. 20, 2025 /PRNewswire/ — Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and Digital Executive Agency (HaDEA) as contracting authority under a joint tender of up to €24 million. The funding is made available through the EU4Health programme, linked to the key priorities of the Health Emergency Preparedness and Response Authority (HERA) of the European Commission.

The partnership, RApid Next Generation Sequencing for Effective Medical Response (RANGER), aims to develop a rapid, point-of-care metagenomic next-generation sequencing (mNGS) solution that enables hospitals and other healthcare facilities to achieve rapid turnaround diagnostics for respiratory viruses – capabilities that move us closer to a “Star Trek tricorder”- style tool for biosecurity and public health. Under this award, Ginkgo and its consortium partners are eligible to receive up to €24 million over the next 4 years.

RANGER seeks to transform the diagnostic landscape, enabling clinicians to diagnose complex respiratory conditions quickly and efficiently at the bedside with a device that allows for fully automated push-button sample preparation. With 6-hour turnaround time, hospitals could gain critical flexibility and optionality, allowing them to rapidly triage patients and reduce the burden of prolonged isolation, empirical therapies, and costly inpatient stays.

“Agnostic diagnostics” means the device wouldn’t just look for a handful of known targets; it could sequence and identify virtually any respiratory pathogen, including emergent or engineered pathogens. This could significantly enhance pandemic preparedness. The program also offers the European Commission the option to procure 200 devices at preferred pricing, which could enable widespread and scalable deployment across EU/EEA healthcare systems.

The program is designed to be delivered in three phases. In the first phase, Ginkgo will work with a consortium of technology partners – Jumpcode, TGen, Bugseq, and Planet Innovation – to bring together existing technologies at different stages of technology readiness in one benchtop device. That device will then be taken through clinical trials in hospital settings in the EU in partnership with KU Leuven (Belgium), Karolinska University Hospital (Sweden), and Tartu University Hospital (Estonia) during the second phase of the program. Once clinical trials have been satisfactorily completed, Ginkgo will collaborate with medical device regulatory specialists at the QbD Group to secure EU certification and validation for certain analytes and sample types before bringing the RANGER device to market.

This collaboration aligns with HERA’s mission to strengthen Europe’s ability to prevent, detect, and rapidly respond to cross-border health emergencies, as it seeks to expand the availability of and access to key medical countermeasures. By supporting the development of near-patient sequencing capabilities, HERA and HaDEA aim to reduce diagnostic delays, enhance hospital triage and infection control, and provide a powerful early-warning tool against emerging pathogens. “Diagnostics as decision making tools are a key component of our toolbox to rapidly respond to health emergencies. The ability to quickly identify even previously unknown pathogens will be a critical step in reinforcing the EU’s collective health resilience,” said Laurent Muschel, Acting Director-General of HERA.

“HaDEA is committed to fostering innovative solutions that can strengthen Europe’s capacity to prevent, detect, and respond to biological threats,” said Marina Zanchi – Director of HADEA. “This project represents a leap forward in leveraging next-generation sequencing at the bedside, and we believe the collaborative approach taken by Ginkgo and its partners will greatly accelerate the path toward safer, more prepared healthcare systems across the region.”

“This collaboration with HaDEA embodies our mission at Ginkgo Biosecurity to arm global healthcare systems with cutting-edge capabilities,” said Matt McKnight, General Manager of Ginkgo Biosecurity. “Instead of waiting days to confirm a diagnosis, we want doctors to be able to run a sample through this machine and get results in about 6 hours. Ultimately, this means faster triage, better patient outcomes, and a more resilient frontline response to both seasonal viruses and future pandemics.”

“We’re moving toward a diagnostic model that’s as easy and quick as scanning a patient’s sample right on the spot,” added Dr. Nita Madhav, Head of Epidemiology & Global Risk Analytics at Ginkgo Bioworks. “The European Commission’s decision to fund this effort not only accelerates access to innovative medical countermeasures but also enables a step-change in how we detect and respond to novel respiratory pathogens. Our integrated approach—incorporating metagenomic sequencing, computational design, and predictive analytics—will help clinicians and public health leaders stay ahead of the curve.”

“We’re excited to be part of the RANGER consortium, which in partnership with Jumpcode’s CRISPR-based technology, represents a significant advancement in diagnostic capabilities. By enabling faster and more comprehensive pathogen detection through our Cipher system, we’re taking an important step forward in improving clinical diagnostics and enhancing pandemic preparedness,” said Mike Salter, CEO of Jumpcode Genomics.

“TGen is focused on translating genomic findings to the clinic and the RANGER project and the outstanding collaborators involved are excellent vehicles for setting precedents in the translational research space” says Dr. Nicholas J. Schork, Professor at TGen whose lab published findings with Jumpcode on the initial version of the system to be developed and evaluated in the proposed research.

“BugSeq is thrilled to partner with RANGER consortium members to deploy our clinically-tailored bioinformatics platform to advance the use of rapid metagenomic sequencing for infectious disease diagnostics,” said Sam Chorlton, CEO of BugSeq. “This collaborative effort to develop a seamless, end-to-end solution marks a significant step forward in accelerating the adoption of agnostic diagnostics and strengthening our ability to respond swiftly to public health emergencies.”

“Planet Innovation is proud to be a part of the RANGER consortium, and will leverage its large product development and manufacturing capabilities in developing the highly innovative Cipher system. Planet Innovation has extensive experience in developing world-class platforms and we look forward to working alongside Jumpcode Genomics and all the consortium members in delivering a diagnostic solution that provides better patient outcomes, and a more resilient frontline response to both seasonal viruses and future pandemics,” said Stuart Elliott, CEO of Planet Innovation.

To learn more about how you can benefit from Ginkgo Biosecurity, please visit our website at https://biosecurity.ginkgo.bio.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

GINKGO BIOWORKS INVESTOR CONTACT:

[email protected]

GINKGO BIOWORKS MEDIA CONTACT:

[email protected]

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo’s cell programming platform. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 29, 2024, Ginkgo’s most recent quarterly report on Form 10-Q, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-partners-with-hadea-in-up-to-24-million-consortium-project-to-deliver-next-generation-agnostic-diagnostics-for-respiratory-viruses-at-the-point-of-care-302381350.html

SOURCE Ginkgo Bioworks